U.S. & EU Pediatric Drug Regulators Strive For Dialogue, Not Harmonization

Though differences in timing and design of pediatric oncology trials within U.S. and Europe regulatory frameworks may make harmonization of trial requirements impossible, they should be seen as opportunities to expand understanding of drug development in the field, FDA said at an April 16 meeting of the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet